<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32014438</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2430</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Experimental neurology</Title><ISOAbbreviation>Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the NAD<sup>+</sup> biosynthetic pathway in ALS patients and effect of modulating NAD<sup>+</sup> levels in hSOD1-linked ALS mouse models.</ArticleTitle><Pagination><StartPage>113219</StartPage><MedlinePgn>113219</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2020.113219</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0014-4886(20)30050-9</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is characterized by progressive degeneration of motor neurons. Astrocytes from diverse ALS models induce motor neuron death in co-culture. Enhancing NAD<sup>+</sup> availability, or increasing the expression of the NAD<sup>+</sup>-dependent deacylases SIRT3 and SIRT6, abrogates their neurotoxicity in cell culture models. To determine the effect of increasing NAD<sup>+</sup> availability in ALS mouse models we used two strategies, ablation of a NAD<sup>+</sup>-consuming enzyme (CD38) and supplementation with a bioavailable NAD<sup>+</sup> precursor (nicotinamide riboside, NR). Deletion of CD38 had no effect in the survival of two hSOD1-linked ALS mouse models. On the other hand, NR-supplementation delayed motor neuron degeneration, decreased markers of neuroinflammation in the spinal cord, appeared to modify muscle metabolism and modestly increased the survival of hSOD1<sup>G93A</sup> mice. In addition, we found altered expression of enzymes involved in NAD<sup>+</sup> synthesis (NAMPT and NMNAT2) and decreased SIRT6 expression in the spinal cord of ALS patients, suggesting deficits of this neuroprotective pathway in the human pathology. Our data denotes the therapeutic potential of increasing NAD<sup>+</sup> levels in ALS. Moreover, the results indicate that the approach used to enhance NAD<sup>+</sup> levels critically defines the biological outcome in ALS models, suggesting that boosting NAD<sup>+</sup> levels with the use of bioavailable precursors would be the preferred therapeutic strategy for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harlan</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Killoy</LastName><ForeName>Kelby M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pehar</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auwerx</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Integrative and Systems Physiology, Institute of Bioengineering, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Marcelo R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA. Electronic address: mvargas@wisc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM103542</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA138313</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089640</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018113</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Exp Neurol</MedlineTA><NlmUniqueID>0370712</NlmUniqueID><ISSNLinking>0014-4886</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0U46U6E8UK</RegistryNumber><NameOfSubstance UI="D009243">NAD</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.12</RegistryNumber><NameOfSubstance UI="D054409">Nicotinamide Phosphoribosyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.1</RegistryNumber><NameOfSubstance UI="C484008">NMNAT2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.1</RegistryNumber><NameOfSubstance UI="D009612">Nicotinamide-Nucleotide Adenylyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C516592">SIRT6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056566">Sirtuin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053898" MajorTopicYN="N">Biosynthetic Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054409" MajorTopicYN="N">Nicotinamide Phosphoribosyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009612" MajorTopicYN="N">Nicotinamide-Nucleotide Adenylyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056566" MajorTopicYN="N">Sirtuin 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="N">Sirtuins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Astrocytes</Keyword><Keyword MajorTopicYN="N">Motor neurons</Keyword><Keyword MajorTopicYN="N">NMNAT2</Keyword><Keyword MajorTopicYN="N">Nicotinamide riboside</Keyword><Keyword MajorTopicYN="N">SIRT3</Keyword><Keyword MajorTopicYN="N">SIRT6</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32014438</ArticleId><ArticleId IdType="mid">NIHMS1558547</ArticleId><ArticleId IdType="pmc">PMC7089832</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2020.113219</ArticleId><ArticleId IdType="pii">S0014-4886(20)30050-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abeti R, Abramov AY, Duchen MR, 2011. Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain : a journal of neurology 134, 1658&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pubmed">21616968</ArticleId></ArticleIdList></Reference><Reference><Citation>Adebanjo OA, Anandatheerthavarada HK, Koval AP, Moonga BS, Biswas G, Sun L, Sodam BR, Bevis PJ, Huang CL, Epstein S, Lai FA, Avadhani NG, Zaidi M, 1999. A new function for CD38/ADP-ribosyl cyclase in nuclear Ca2+ homeostasis. Nat Cell Biol 1, 409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559984</ArticleId></ArticleIdList></Reference><Reference><Citation>Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O&#x2019;Brien KD, 2017. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PloS one 12, e0186459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718430</ArticleId><ArticleId IdType="pubmed">29211728</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksoy P, White TA, Thompson M, Chini EN, 2006. Regulation of intracellular levels of NAD: a novel role for CD38. Biochemical and biophysical research communications 345, 1386&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16730329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali YO, Allen HM, Yu L, Li-Kroeger D, Bakhshizadehmahmoudi D, Hatcher A, McCabe C, Xu J, Bjorklund N, Taglialatela G, Bennett DA, De Jager PL, Shulman JM, Bellen HJ, Lu HC, 2016. NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies. PLoS biology 14, e1002472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890852</ArticleId><ArticleId IdType="pubmed">27254664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali YO, Li-Kroeger D, Bellen HJ, Zhai RG, Lu HC, 2013. NMNATs, evolutionarily conserved neuronal maintenance factors. Trends in neurosciences 36, 632&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857727</ArticleId><ArticleId IdType="pubmed">23968695</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, Szabo C, Beal MF, 2001. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Experimental neurology 168, 419&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259130</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenky P, Bogan KL, Brenner C, 2007a. NAD+ metabolism in health and disease. Trends in biochemical sciences 32, 12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">17161604</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, Brenner C, 2007b. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129, 473&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482543</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger F, Ramirez-Hernandez MH, Ziegler M, 2004. The new life of a centenarian: signalling functions of NAD(P). Trends in biochemical sciences 29, 111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003268</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger NA, Besson VC, Boulares AH, Burkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Hasko G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sumegi B, Swanson RA, Szabo C, 2018. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175, 192&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758399</ArticleId><ArticleId IdType="pubmed">28213892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieganowski P, Brenner C, 2004. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117, 495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">15137942</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M, Zabari M, Brik RB, Kviatcovsky D, Zmora N, Cohen Y, Bar N, Levi I, Amar N, Mehlman T, Brandis A, Biton I, Kuperman Y, Tsoory M, Alfahel L, Harmelin A, Schwartz M, Israelson A, Arike L, Johansson MEV, Hansson GC, Gotkine M, Segal E, Elinav E, 2019. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 572, 474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Dadali T, Bespalko A, Haupenthal VJ, Grimm MO, Hartmann T, Lund FE, Stein R, Levy A, 2015. Alzheimer&#x2019;s disease pathology is attenuated in a CD38-deficient mouse model. Annals of neurology 78, 88&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929692</ArticleId><ArticleId IdType="pubmed">25893674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolanos JP, Almeida A, Moncada S, 2010. Glycolysis: a bioenergetic or a survival pathway? Trends in biochemical sciences 35, 145&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">20006513</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A, 2017. Amyotrophic Lateral Sclerosis. N Engl J Med 377, 162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck E, Bayer H, Lindenberg KS, Hanselmann J, Pasquarelli N, Ludolph AC, Weydt P, Witting A, 2017. Comparison of Sirtuin 3 Levels in ALS and Huntington&#x2019;s Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models. Front Mol Neurosci 10, 156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5445120</ArticleId><ArticleId IdType="pubmed">28603486</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, Auwerx J, 2012. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell metabolism 15, 838&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616313</ArticleId><ArticleId IdType="pubmed">22682224</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto C, Menzies KJ, Auwerx J, 2015. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell metabolism 22, 31&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487780</ArticleId><ArticleId IdType="pubmed">26118927</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale A, Paldino E, Giampa C, Bernardi G, Fusco FR, 2015. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington&#x2019;s Disease. PloS one 10, e0134482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529170</ArticleId><ArticleId IdType="pubmed">26252217</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti L, Gilley J, Coleman MP, 2014. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nature reviews. Neuroscience 15, 394&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">24840802</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer AS, Koszka K, Kiskinis E, Suzuki N, Davis-Dusenbery BN, Eggan K, 2014. Genetic validation of a therapeutic target in a mouse model of ALS. Sci Transl Med 6, 248ra104.</Citation><ArticleIdList><ArticleId IdType="pubmed">25100738</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Rubia JE, Drehmer E, Platero JL, Benlloch M, Caplliure-Llopis J, Villaron-Casales C, de Bernardo N, AlarcOn J, Fuente C, Carrera S, Sancho D, GarcIa-Pardo P, Pascual R, JuArez M, Cuerda-Ballester M, Forner A, Sancho-Castillo S, Barrios C, Obrador E, Marchio P, Salvador R, Holmes HE, Dellinger RW, Guarente L, Estrela JM, 2019. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration 20, 115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">30668199</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E, 2017. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis 3, 17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5701244</ArticleId><ArticleId IdType="pubmed">29184669</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stefano M, Conforti L, 2013. Diversification of NAD biological role: the importance of location. The FEBS journal 280, 4711&#x2013;4728.</Citation><ArticleIdList><ArticleId IdType="pubmed">23848828</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittenhafer-Reed KE, Richards AL, Fan J, Smallegan MJ, Fotuhi Siahpirani A, Kemmerer ZA, Prolla TA, Roy S, Coon JJ, Denu JM, 2015. SIRT3 mediates multi-tissue coupling for metabolic fuel switching. Cell metabolism 21, 637&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393847</ArticleId><ArticleId IdType="pubmed">25863253</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP, 2004. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America 101, 11159&#x2013;11164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG, 2019. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep 28, 1717&#x2013;1728 e1716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6702140</ArticleId><ArticleId IdType="pubmed">31412242</ArticleId></ArticleIdList></Reference><Reference><Citation>Garten A, Petzold S, Korner A, Imai S, Kiess W, 2009. Nampt: linking NAD biology, metabolism and cancer. Trends in endocrinology and metabolism: TEM 20, 130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738422</ArticleId><ArticleId IdType="pubmed">19109034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdts J, Summers DW, Milbrandt J, DiAntonio A, 2016. Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism. Neuron 89, 449&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742785</ArticleId><ArticleId IdType="pubmed">26844829</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Mayer PR, Yu G, Coleman MP, 2019. Low levels of NMNAT2 compromise axon development and survival. Human molecular genetics 28, 448&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">30304512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, Wang J, Sastre M, Ono K, Sauve AA, Pasinetti GM, 2013. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer&#x2019;s mouse models. Neurobiology of aging 34, 1581&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632303</ArticleId><ArticleId IdType="pubmed">23312803</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez de Aguilar JL, Niederhauser-Wiederkehr C, Halter B, De Tapia M, Di Scala F, Demougin P, Dupuis L, Primig M, Meininger V, Loeffler JP, 2008. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol Genomics 32, 207&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">18000159</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al., 1994. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, Song S, Likhite S, Murtha MJ, Foust KD, Rao M, Eagle A, Kammesheidt A, Christensen A, Mendell JR, Burghes AH, Kaspar BK, 2011. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nature biotechnology 29, 824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Pehar M, Killoy KM, Vargas MR, 2019. Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 33, 7084&#x2013;7091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529338</ArticleId><ArticleId IdType="pubmed">30841754</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Pehar M, Sharma DR, Beeson G, Beeson CC, Vargas MR, 2016. Enhancing NAD+ Salvage Pathway Reverts the Toxicity of Primary Astrocytes Expressing Amyotrophic Lateral Sclerosis-linked Mutant Superoxide Dismutase 1 (SOD1). The Journal of biological chemistry 291, 10836&#x2013;10846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, Ji X, Lo EH, 2016. Transfer of mitochondria from astrocytes to neurons after stroke. Nature 535, 551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968589</ArticleId><ArticleId IdType="pubmed">27466127</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskovits AZ, Hunter TA, Maxwell N, Pereira K, Whittaker CA, Valdez G, Guarente LP, 2018. SIRT1 deacetylase in aging-induced neuromuscular degeneration and amyotrophic lateral sclerosis. Aging cell 17, e12839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260920</ArticleId><ArticleId IdType="pubmed">30295421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, Zhang Y, Moritoh K, O&#x2019;Connell JF, Baptiste BA, Stevnsner TV, Mattson MP, Bohr VA, 2018. NAD(+) supplementation normalizes key Alzheimer&#x2019;s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proceedings of the National Academy of Sciences of the United States of America 115, E1876&#x2013;E1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828618</ArticleId><ArticleId IdType="pubmed">29432159</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai S, Guarente L, 2014. NAD+ and sirtuins in aging and disease. Trends in cell biology 24, 464&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112140</ArticleId><ArticleId IdType="pubmed">24786309</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O, Shnayder NA, Yamada K, Noda M, Seike T, Fujita K, Takasawa S, Yokoyama S, Koizumi K, Shiraishi Y, Tanaka S, Hashii M, Yoshihara T, Higashida K, Islam MS, Yamada N, Hayashi K, Noguchi N, Kato I, Okamoto H, Matsushima A, Salmina A, Munesue T, Shimizu N, Mochida S, Asano M, Higashida H, 2007. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446, 41&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287729</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing Z, Xing J, Chen X, Stetler RA, Weng Z, Gan Y, Zhang F, Gao Y, Chen J, Leak RK, Cao G, 2014. Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 34, 1613&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4269719</ArticleId><ArticleId IdType="pubmed">25005877</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsyuba E, Auwerx J, 2017. Modulating NAD(+) metabolism, from bench to bedside. The EMBO journal 36, 2670&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599801</ArticleId><ArticleId IdType="pubmed">28784597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauppinen TM, Suh SW, Higashi Y, Berman AE, Escartin C, Won SJ, Wang C, Cho SH, Gan L, Swanson RA, 2011. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid beta. J Neuroinflammation 8, 152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3247192</ArticleId><ArticleId IdType="pubmed">22051244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia A, McAvoy K, Krishnamurthy K, Trotti D, Pasinelli P, 2018. Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. Glia 66, 1016&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873384</ArticleId><ArticleId IdType="pubmed">29380416</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Kim T, Lee HR, Jang EH, Ryu HH, Kang M, Rah SY, Yoo J, Lee B, Kim JI, Lim CS, Kim SJ, Kim UH, Lee YS, Kaang BK, 2016. Impaired learning and memory in CD38 null mutant mice. Molecular brain 9, 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4746819</ArticleId><ArticleId IdType="pubmed">26856703</ArticleId></ArticleIdList></Reference><Reference><Citation>Korner S, Boselt S, Thau N, Rath KJ, Dengler R, Petri S, 2013. Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neuro-degenerative diseases 11, 141&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">22796962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautrup S, Sinclair DA, Mattson MP, Fang EF, 2019. NAD(+) in Brain Aging and Neurodegenerative Disorders . Cell metabolism 30, 630&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787556</ArticleId><ArticleId IdType="pubmed">31577933</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacs M, Gilley J, Zhu Y, Orsomando G, Angeletti C, Liu J, Yang X, Park J, Hopkin RJ, Coleman MP, Zhai RG, Stottmann RW, 2019. Severe biallelic loss-of-function mutations in nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) in two fetuses with fetal akinesia deformation sequence. Experimental neurology 320, 112961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6708453</ArticleId><ArticleId IdType="pubmed">31136762</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundsgaard AM, Fritzen AM, Kiens B, 2018. Molecular Regulation of Fatty Acid Oxidation in Skeletal Muscle during Aerobic Exercise. Trends in endocrinology and metabolism: TEM 29, 18&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29221849</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, Lorenzini I, Barrameda D, O&#x2019;Conner AG, Barrows JM, Starr A, Kovalik T, Rabichow BE, Lehmkuhl EM, Shreiner DD, Joardar A, Lievens JC, Bowser R, Sattler R, Zarnescu DC, 2019. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR, 2018. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nature communications 9, 1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876407</ArticleId><ArticleId IdType="pubmed">29599478</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K, Ferraiuolo L, Miranda CJ, Likhite S, McElroy S, Renusch S, Ditsworth D, Lagier-Tourenne C, Smith RA, Ravits J, Burghes AH, Shaw PJ, Cleveland DW, Kolb SJ, Kaspar BK, 2014. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proceedings of the National Academy of Sciences of the United States of America 111, 829&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI, 2016. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell metabolism 24, 795&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668137</ArticleId><ArticleId IdType="pubmed">28068222</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E, Cassina A, Martinez-Palma L, Souza JM, Bolatto C, Rodriguez-Bottero S, Logan A, Smith RA, Murphy MP, Barbeito L, Radi R, Cassina P, 2014. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free radical biology &amp; medicine 70, 204&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">24582549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, Guarente L, Auwerx J, 2013. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell 154, 430&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753670</ArticleId><ArticleId IdType="pubmed">23870130</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S, 2007. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature neuroscience 10, 615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, Boutillier AL, Zoll J, Echaniz-Laguna A, Loeffler JP, Rene F, 2015. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med 7, 526&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E, Reyes-Ruiz JM, Lopergolo D, Roseti C, Bertollini C, Ruffolo G, Cifelli P, Onesti E, Limatola C, Miledi R, Inghilleri M, 2016. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proceedings of the National Academy of Sciences of the United States of America 113, 3060&#x2013;3065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801305</ArticleId><ArticleId IdType="pubmed">26929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Partida-Sanchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, Kusser K, Goodrich S, Howard M, Harmsen A, Randall TD, Lund FE, 2001. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nature medicine 7, 1209&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689885</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Beeson G, Beeson CC, Johnson JA, Vargas MR, 2014. Mitochondria-Targeted Catalase Reverts the Neurotoxicity of hSOD1G93A Astrocytes without Extending the Survival of ALS-Linked Mutant hSOD1 Mice. PloS one 9, e103438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108402</ArticleId><ArticleId IdType="pubmed">25054289</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Harlan BA, Killoy KM, Vargas MR, 2018. Nicotinamide Adenine Dinucleotide Metabolism and Neurodegeneration. Antioxidants &amp; redox signaling 28, 1652&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962335</ArticleId><ArticleId IdType="pubmed">28548540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L, Mitsumoto H, Przedborski S, Rothstein J, Trojanowski JQ, van den Berg LH, Ringel S, 2013. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration 14 Suppl 1, 5&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779649</ArticleId><ArticleId IdType="pubmed">23678876</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ, 2014. State of play in amyotrophic lateral sclerosis genetics. Nature neuroscience 17, 17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O&#x2019;Regan JP, Deng HX, et al., 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA, 2006. Tryptophan metabolism in the central nervous system: medical implications. Expert reviews in molecular medicine 8, 1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16942634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Vohra BP, Lund FE, Milbrandt J, 2009. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. The Journal of neuroscience : the official journal of the Society for Neuroscience 29, 5525&#x2013;5535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162248</ArticleId><ArticleId IdType="pubmed">19403820</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj V, Soundarapandian MM, Chechneva O, Williams AJ, Sidorov MK, Soulika AM, Pleasure DE, Deng W, 2009. PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. The Journal of biological chemistry 284, 26070&#x2013;26084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758007</ArticleId><ArticleId IdType="pubmed">19628872</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S, Miranda CJ, Braun L, Meyer K, Frakes AE, Ferraiuolo L, Likhite S, Bevan AK, Foust KD, McConnell MJ, Walker CM, Kaspar BK, 2016. Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nature medicine 22, 397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823173</ArticleId><ArticleId IdType="pubmed">26928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E, 2013. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1alpha. Neurobiology of disease 51, 72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992938</ArticleId><ArticleId IdType="pubmed">22819776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino V, Romani M, Mouchiroud L, Beck JS, Zhang H, D&#x2019;Amico D, Moullan N, Potenza F, Schmid AW, Rietsch S, Counts SE, Auwerx J, 2017. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity. Nature 552, 187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5730497</ArticleId><ArticleId IdType="pubmed">29211722</ArticleId></ArticleIdList></Reference><Reference><Citation>Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C, 2016. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature communications 7, 12948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062546</ArticleId><ArticleId IdType="pubmed">27721479</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA, 2008. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience 28, 13574&#x2013;13581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Pehar M, Cassina P, Beckman JS, Barbeito L, 2006. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis. Journal of neurochemistry 97, 687&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li H, Ding S, 2016. Pre-B-cell colony-enhancing factor protects against apoptotic neuronal death and mitochondrial damage in ischemia. Sci Rep 6, 32416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006239</ArticleId><ArticleId IdType="pubmed">27576732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhang Q, Bao R, Zhang N, Wang Y, Polo-Parada L, Tarim A, Alemifar A, Han X, Wilkins HM, Swerdlow RH, Wang X, Ding S, 2017. Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death. Cell Rep 20, 2184&#x2013;2200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021762</ArticleId><ArticleId IdType="pubmed">28854367</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Ageta-Ishihara N, Nagatsu S, Takao K, Komine O, Endo F, Miyakawa T, Misawa H, Takahashi R, Kinoshita M, Yamanaka K, 2014. SIRT1 overexpression ameliorates a mouse model of SOD1-linked amyotrophic lateral sclerosis via HSF1/HSP70i chaperone system. Molecular brain 7, 62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237944</ArticleId><ArticleId IdType="pubmed">25167838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Lu Y, Hao B, Zhang K, Wang Q, Miller AL, Zhang LR, Zhang LH, Yue J, 2015. CD38 Is Required for Neural Differentiation of Mouse Embryonic Stem Cells by Modulating Reactive Oxygen Species. Stem cells 33, 2664&#x2013;2673.</Citation><ArticleIdList><ArticleId IdType="pubmed">26012865</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J, Mills KF, Yoon MJ, Imai S, 2011. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell metabolism 14, 528&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204926</ArticleId><ArticleId IdType="pubmed">21982712</ArticleId></ArticleIdList></Reference><Reference><Citation>Young GS, Choleris E, Lund FE, Kirkland JB, 2006. Decreased cADPR and increased NAD+ in the Cd38&#x2212;/&#x2212; mouse. Biochemical and biophysical research communications 346, 188&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16750163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, Bellen HJ, 2008. NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature 452, 887&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150538</ArticleId><ArticleId IdType="pubmed">18344983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, D&#x2019;Amico D, Ropelle ER, Lutolf MP, Aebersold R, Schoonjans K, Menzies KJ, Auwerx J, 2016. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">27127236</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>